When do severe RSV outcomes peak in infants in low-income countries?
Respiratory syncytial virus (RSV) causes the most severe disease in infants living in low-income and middle-income countries. Research shows that the highest risk for serious illness occurs very early in life, specifically before an infant reaches their first birthday. This timing is critical for deciding when to give preventive treatments like monoclonal antibodies.
What the research says
Studies analyzing data from low-income countries found that the peak age for community infections is around 4.8 months. However, when looking at more severe outcomes like hospitalization and in-hospital death, the peak shifts to a younger age. One analysis estimated the peak age for these severe outcomes to be 2.6 months 6. Another large meta-analysis confirmed that severe outcomes peak in early infancy, supporting the recommendation to protect infants younger than 6 months 17.
What to ask your doctor
- At what age does my infant become eligible for RSV preventive shots in our region?
- How does the peak age for severe RSV in low-income countries affect the timing of treatment for my child?
- What is the duration of protection offered by the RSV vaccine or antibody we are considering?
- Are there specific signs of severe RSV I should watch for in the first few months of life?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.